OBJECTIVES: The systemic inflammatory response syndrome (SIRS) after cardiac surgery with cardiopulmonary bypass (CPB) exacerbates organ dysfunction and increases postoperative mortality. The aim of this study was to reduce SIRS after CPB in a pig model by profoundly decreasing all blood defence factors (complement, coagulation and fibrinolytic and contact systems, leukocytes and thrombocytes) using pre‑operative aphaeresis. METHODS: Thirty-three pigs underwent 3 h of hypothermic CPB with 2 h of cardioplegic arrest, followed by 4 days of observation. One half of the sample underwent prebypass plasma-thrombo-leukocyte aphaeresis with the adjuvant leukofiltration. RESULTS: In the control group, there were classical signs of SIRS (tachycardia, tachypnea and leukocytosis) postoperatively. There was also myocardial ischaemia and the need for inotropic support in 90% of the control animals. Neutrophils showed an increase in superoxide anion production (P < 0.001), and surface neutral protease activity (P < 0.001) and blood endotoxin levels increased (P < 0.01) compared with preoperative levels. In contrast, in the aphaeretic group, there were no classical signs of SIRS; no myocardial ischaemia; minimum neutrophil production of the superoxide anion and protease activity were recorded (P < 0.001); and endotoxin levels were also decreased (P < 0.05) compared with the controls. In the control group, the haemodynamic problems associated with disconnecting from CPB correlated with the histologic findings in the myocardium (leukocyte endothelial adhesion and leukodiapedesis). CONCLUSIONS: Pre‑operative plasma‑thrombo-leukocyte aphaeresis significantly reduces the major symptoms of SIRS and organ dysfunction after 3 h of CPB without adverse effects, such as bleeding and infection, during the postoperative course.

• Klíčová slova
• cardiopulmonary bypass, plasma‑thrombo-leukocyte aphaeresis, systemic inflammatory response syndrome,
• MeSH
• ischemická choroba srdeční etiologie   MeSH
• kardiopulmonální bypass metody   MeSH
• krevní plazma MeSH
• leukaferéza metody   MeSH
• leukocyty fyziologie   MeSH
• miniaturní prasata MeSH
• modely nemocí na zvířatech MeSH
• plazmaferéza metody   MeSH
• prasata MeSH
• předoperační období MeSH
• separace krevních složek metody   MeSH
• syndrom systémové zánětlivé reakce prevence a kontrola   MeSH
• terapeutická hypotermie metody   MeSH
• trombocyty MeSH
• vyvolaná zástava srdce metody   MeSH
• zvířata MeSH
• Check Tag
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH

BACKGROUND: The risk of early death (ED) by bleeding/leukostasis is high in patients with AML with hyperleukocytosis (>100,000/μl). Within the pediatric AML-BFM (Berlin-Frankfurt-Münster) 98/04 studies, emergency strategies for these children included exchange transfusion (ET) or leukapheresis (LPh). Risk factors for ED and interventions performed were analyzed. PATIENTS: Two hundred thirty-eight of 1,251 (19%) patients with AML presented with hyperleukocytosis; 23 of 1,251 (1.8%) patients died of bleeding/leukostasis. RESULTS: ED due to bleeding/leukostasis was highest at white blood cell (WBC) count >200,000/μl (14.3%). ED rates were even higher (20%) in patients with FAB (French-American-British) M4/M5 and hyperleukocytosis >200,000/μl. Patients with WBC >200,000/μl did slightly better with ET/LPh compared to those without ET/LPh (ED rate 7.5% vs. 21.2%, P = 0.055). Multivariate WBC >200,000/μl was of strongest prognostic significance for ED (P(χ(2) ) <0.0001). CONCLUSION: Our data confirm the high risk of bleeding/leukostasis in patients with hyperleukocytosis. ET/LPh shows a trend toward reduced ED rate due to bleeding/leukostasis and is recommended at WBC >200,000/μl, and in FAB M4/M5 even at lower WBC.

• Klíčová slova
• bleeding, early death, exchange transfusion, leukapheresis, leukostasis, pediatric AML,
• MeSH
• akutní myeloidní leukemie komplikace   mortalita   terapie   MeSH
• dítě MeSH
• kojenec MeSH
• krevní transfuze * MeSH
• krvácení etiologie   mortalita   prevence a kontrola   MeSH
• leukaferéza * MeSH
• leukostáza etiologie   mortalita   prevence a kontrola   MeSH
• lidé MeSH
• předškolní dítě MeSH
• proporcionální rizikové modely MeSH
• rizikové faktory MeSH
• Check Tag
• dítě MeSH
• kojenec MeSH
• lidé MeSH
• mužské pohlaví MeSH
• předškolní dítě MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH

BACKGROUND: Insufficient future liver remnant volume (FLRV) is the main cause of low resectability of liver metastases from colorectal cancer (CLMs). One option for enhancing FLVR growth is the use of portal vein embolisation (PVE) with the application of autologous haematopoietic stem cells (HSCs). PATIENTS AND METHODS: PVE with the application of HSCs was used in 11 patients (group 1) with primarily non-resectable CLMs due to insufficient FLRV without signs of extrahepatic metastases. The control group (group 2) consisted of 14 patients in whom only PVE was performed. We evaluated the product quality, FLRV growth, CLM volume, median survival and progression-free survival (PFS). RESULTS: Product quality was achieved in all collections. In all group-I patients, sufficient FLRV growth occurred within three weeks. In the first and second weeks, FLRV increased optimally in most patients (p<0.006). In 13 out of the 14 group-2 patients, optimum FLVR growth was observed within three weeks following PVE (p<0.002). More rapid FLVR growth was observed in group 1 patients (p<0.01). CLM volume was significantly increased in both the group-2 (p<0.0005) and group-1 (p<0.008) patients at the time of liver resection. There was no significant difference in the growth of the CLM volume between the groups (p<0.18). The median survival was 7.3 and 6.8 months for group 1 and 2 patients, respectively, and the two-year PFS was 28% and 22% (p<0.18), respectively. CONCLUSION: PVE with HSC application is a promising method for effectively stimulating FLRV growth in patients with primarily non-resectable CLMs.

• Klíčová slova
• Colorectal liver metastases, future liver remnant volume, haematopoietic stem cells, portal vein embolisation,
• MeSH
• hematopoetické kmenové buňky MeSH
• hepatektomie MeSH
• játra krevní zásobení   patologie   chirurgie   MeSH
• kolorektální nádory mortalita   patologie   terapie   MeSH
• leukaferéza MeSH
• lidé středního věku MeSH
• lidé MeSH
• nádory jater mortalita   sekundární   terapie   MeSH
• přežití bez známek nemoci MeSH
• regenerace jater * MeSH
• senioři MeSH
• terapeutická embolizace * MeSH
• transplantace hematopoetických kmenových buněk metody   MeSH
• vena portae MeSH
• Check Tag
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH

Hematopoietic stem cells (HSCs), still represent a certain mystery in biology, have a unique property of dividing into equal cells and repopulating the hematopoietic tissue. This potential enables their use in transplantation treatments. The quality of the HSC grafts for transplantation is evaluated by flow cytometric determination of the CD34(+) cells, which enables optimal timing of the first apheresis and the acquisition of maximal yield of the peripheral blood stem cells (PBSCs). To identify a more efficient method for evaluating CD34(+) cells, we compared the following alternative methods with the reference method: hematopoietic progenitor cells (HPC) enumeration (using the Sysmex XE-2100 analyser), detection of CD133(+) cells, and quantification of aldehyde dehydrogenase activity in the PBSCs. 266 aphereses (84 patients) were evaluated. In the preapheretic blood, the new methods produced data that were in agreement with the reference method. The ROC curves have shown that for the first-day apheresis target, the optimal predictive cut-off value was 0.032 cells/mL for the HPC method (sensitivity 73.4%, specificity 69.3%). HPC method exhibited a definite practical superiority as compared to other methods tested. HPC enumeration could serve as a supplementary method for the optimal timing of the first apheresis; it is simple, rapid, and cheap.

• MeSH
• aldehyddehydrogenasa metabolismus   MeSH
• antigen AC133 MeSH
• antigeny CD34 metabolismus   MeSH
• časové faktory MeSH
• CD antigeny metabolismus   MeSH
• dospělí MeSH
• glykoproteiny metabolismus   MeSH
• hematopoetické kmenové buňky cytologie   metabolismus   MeSH
• leukaferéza MeSH
• lidé středního věku MeSH
• lidé MeSH
• mladý dospělý MeSH
• neparametrická statistika MeSH
• peptidy metabolismus   MeSH
• průtoková cytometrie metody   MeSH
• reprodukovatelnost výsledků MeSH
• ROC křivka MeSH
• senioři MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mladý dospělý MeSH
• mužské pohlaví MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• srovnávací studie MeSH
• Názvy látek
• aldehyddehydrogenasa MeSH
• antigen AC133 MeSH
• antigeny CD34 MeSH
• CD antigeny MeSH
• glykoproteiny MeSH
• peptidy MeSH
• PROM1 protein, human MeSH Prohlížeč

BACKGROUND: The aim of the study was to evaluate the in vitro quality of cryopreserved red blood cells obtained from different sources with or without leucodepletion and stored at 4±2 °C in AS-3 for up to 21 days. MATERIALS AND METHODS: Red blood cells were collected by four methods: double erythrocytapheresis, whole blood collection with buffy coat removal, double erythrocytapheresis with in-line leucofiltration, or whole blood collection with in-line leucofiltration. All four types of red blood cells were frozen in 40% glycerol after collection and stored at a temperature below -65 °C for at least 30 days, thawed, deglycerolised and subsequently reconstituted in AS-3. The in vitro haematological and biochemical properties of the thawed red blood cells were tested on days 0, 7, 14, and 21 after deglycerolisation and reconstitution. RESULTS: Overall, 72 units were processed. Leucodepletion of cryopreserved red blood cells units reduced haemolysis, lowered ammonia concentration, preserved pH and osmolality and led to sustained higher concentrations of ATP. In contrast, the source of red blood cells (apheresis or whole blood) did not affect their quality. DISCUSSION: The quality of all investigated red blood cells units was the same as or even better than that of erythrocytes obtained from double erythrocytapheresis with a 24-hour survival of at least 86% after up to 3 weeks of storage in AS-3.

• MeSH
• adenosintrifosfát krev   MeSH
• amoniak krev   MeSH
• cytaferéza metody   MeSH
• erytrocyty * účinky léků   MeSH
• glycerol farmakologie   MeSH
• hemoglobiny analýza   MeSH
• hemolýza MeSH
• koncentrace vodíkových iontů MeSH
• konzervace krve * MeSH
• kryoprezervace * MeSH
• kryoprotektivní látky farmakologie   MeSH
• leukoredukce * MeSH
• lidé MeSH
• osmolární koncentrace MeSH
• techniky in vitro MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• srovnávací studie MeSH
• Názvy látek
• adenosintrifosfát MeSH
• amoniak MeSH
• glycerol MeSH
• hemoglobiny MeSH
• kryoprotektivní látky MeSH

In the present study, we compared three single platform methods for CD34+ hematopoietic stem cell (HSC) enumeration by flow cytometry. For this purpose, we analyzed the performance characteristics and results obtained from different HSC sources. Interlaboratory coefficients of variation (CV) for precision/reproducibility analysis varied from 4.0% to 6.7% / 6.7% to 9.2% for the low and 3.2% to 4.1% / 4.3% to 6.7%, respectively, for the high stem cell control. Correlation between methods ranged from 0.92% to 0.99%; Wilcoxon test showed no significant differences (p > 0.05); Bland-Altman analysis confirmed good agreement between assays (mean bias ranging from -0.48 to 6.91). Our results demonstrate very good intralaboratory correlation and agreement between methods, confirm the major impact of single platform strategy for accurate and reproducible HSC enumeration and suggest that high interlaboratory variability could be influenced by incorrect performance of validated methods.

• MeSH
• antigeny CD34 analýza   imunologie   MeSH
• buňky kostní dřeně MeSH
• daktinomycin analogy a deriváty   MeSH
• faktor stimulující kolonie granulocytů farmakologie   MeSH
• fluorescein-5-isothiokyanát MeSH
• fluorescenční barviva MeSH
• fykoerythrin MeSH
• hematopoetické kmenové buňky * MeSH
• krevní buňky MeSH
• krevní obraz MeSH
• laboratoře MeSH
• leukaferéza MeSH
• lidé MeSH
• mobilizace hematopoetických kmenových buněk MeSH
• monoklonální protilátky imunologie   MeSH
• počet buněk metody   MeSH
• protinádorové látky farmakologie   MeSH
• průtoková cytometrie metody   MeSH
• reprodukovatelnost výsledků MeSH
• senzitivita a specificita MeSH
• specificita protilátek MeSH
• vyšetřování kostní dřeně MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• hodnotící studie MeSH
• srovnávací studie MeSH
• Názvy látek
• 7-aminoactinomycin D MeSH Prohlížeč
• antigeny CD34 MeSH
• daktinomycin MeSH
• faktor stimulující kolonie granulocytů MeSH
• fluorescein-5-isothiokyanát MeSH
• fluorescenční barviva MeSH
• fykoerythrin MeSH
• monoklonální protilátky MeSH
• protinádorové látky MeSH

BACKGROUND: Peripheral blood stem cells are an important source of hematopoietic stem cells (HSCs) for allogeneic transplantations. Some allogeneic donors mobilize HSCs poorly in response to the granulocyte--colony-stimulating factor (G-CSF). The estimation of the mobilization result in an individual donor is difficult due to the absence of suitable predictive factors. STUDY DESIGN AND METHODS: We analyzed the concentrations and kinetics of certain cytokines induced by G-CSF in 76 healthy donors and compared them with the mobilization efficiency. RESULTS: The levels of the most cytokines increased after the G-CSF application: sICAM, sVCAM, MMP-9, interleukin (IL)-6, TNF-α, sE-selectin, and fibronectin. The concentrations of SDF-1α and IL-8 decreased and VEGF and fractalkine remained unchanged. The premobilization concentrations of IL-6 (p = 0.0093) and TNF-a (p = 0.0006) correlated with preapheresis CD34+ cell count. The comparison of premobilization cytokine levels between better and worse mobilizers showed a difference for TNF-α (p = 0.0006) and IL-6 (p = 0.0682). The TNF-α level below cutoff of 3.6 pg/mL implied approximately 20 times higher risk of poor mobilization (odds ratio, 19.9; p = 0.0002). The immunophenotyping of CD34+ cells suggested a negative correlation between Day +5 CD34+ count and expression of CD11a (p = 0.0319) and a positive correlation with CD44 antigen expression (p = 0.0096). CONCLUSION: The concentrations of certain cytokines corresponded to the quality of HSC mobilization in healthy donors. Their levels measured before mobilization could probably serve as predictive factors for mobilization efficacy and prospectively detect donors who might profit from new mobilization molecules.

• MeSH
• časové faktory MeSH
• cytokiny krev   MeSH
• dárci krve * MeSH
• dospělí MeSH
• faktor stimulující kolonie granulocytů farmakologie   MeSH
• filgrastim MeSH
• hematopoetické kmenové buňky účinky léků   MeSH
• imunofenotypizace MeSH
• krevní obraz MeSH
• leukaferéza MeSH
• lidé středního věku MeSH
• lidé MeSH
• mladý dospělý MeSH
• mobilizace hematopoetických kmenových buněk * MeSH
• prospektivní studie MeSH
• rekombinantní proteiny MeSH
• transplantace periferních kmenových buněk MeSH
• výběr dárců * MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mladý dospělý MeSH
• mužské pohlaví MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• Názvy látek
• cytokiny MeSH
• faktor stimulující kolonie granulocytů MeSH
• filgrastim MeSH
• rekombinantní proteiny MeSH

We evaluated the efficiency, safety and risks of three techniques which were used for autologous PBPC collections: (a) large-volume leukapheresis (LVL), (b) standard collections, and (c) a new modified technique which was named as "Mixed" collections. In spite of the fact that the standard and LVL collection techniques are used routinely, there may occur special conditions in which the procedures cannot be recommended. Some patients may suffer from serious clinical complications and they cannot tolerate either standard procedures with administration of higher doses of ACD-A, or the high extent of procedure in the course of LVL. We tried to find the safe and efficient collection technique which could help this group of patients to overcome their problems. The "Mixed" collection technique could be such a choice. The numbers of 136 autologous PBPC collections were performed in 98 patients who suffered from hemato-oncological diseases. We evaluated the results of (a) 93 LVL (more than 3 TBV, total blood volumes of the patients were processed; anticoagulation: ACD-A and Heparin), (b) 16 Standard procedures (less than 3 TBV were processed; anticoagulation: ACD-A), and (c) 27 "Mixed" collections (less than 3 TBV of patients were processed; anticoagulation: ACD-A+ Heparin). Collections were performed by the use of separator Cobe Spectra, Caridian. In patients (a) with a good effect of mobilization (precollection CD 34+ cells in blood higher than 20×10(3)/mL) we prepared almost the same median dose of CD 34+ cells from the standard and "Mixed" collections, 3.8 and 4×10(6)/kg, respectively. In LVL the median yield of CD 34+ cells was 8.2×10(6)/kg. In patients (b) who were mobilized weakly (precollection CD 34+ cells in blood lower than 20×10(3)/mL), LVL enabled to prepare 1.5×10(6) of CD 34+/kg from one collection, while the median yield of CD 34+ cells from the standard and "Mixed" collections was 0.9 and 1.2×10(6)/kg. All the standard, LVL and "Mixed" procedures were tolerated well without any serious adverse reactions. We detected 22 adverse reactions, but only three reactions were associated directly with the procedure. Mild hypocalcemia (2) and hypotensive reaction (1) were transient and treated efficiently. Procedures could continue and were finished according to the planned programme. Other reactions were related either to the insufficient function of central venous catheter or to the poor clinical condition of the patients. LVL enabled to get a higher yield of CD 34+ cells than the Standard and "Mixed" collections in well mobilized patients as well as in weakly mobilized patients. We observed the similar efficiency in standard and "Mixed" collections in well mobilized and weakly mobilized patients. We can recommend LVL in all patients who can tolerate it due to a greater chance of collecting higher yields of progenitor cells. In the weakly mobilized patients LVL offers a greater chance of collecting at least a minimum amount of CD 34+ cells needed for transplantation. "Mixed" collections may be used as an alternative technique under the circumstances in which standard or LVL cannot be recommended - like in patients who do not tolerate a high amount of citrate or a high extent of the procedure, e.g. patients with cardiac arrhytmia, impaired liver or renal function or unstable vital signs.

• MeSH
• antigeny CD34 biosyntéza   MeSH
• dospělí MeSH
• kmenové buňky cytologie   MeSH
• konzervace krve MeSH
• lékařská onkologie metody   MeSH
• leukaferéza metody   MeSH
• lidé středního věku MeSH
• lidé MeSH
• mobilizace hematopoetických kmenových buněk metody   MeSH
• nádory terapie   MeSH
• riziko MeSH
• senioři MeSH
• transplantace periferních kmenových buněk přístrojové vybavení   metody   MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• Názvy látek
• antigeny CD34 MeSH

Here we report response to treatment of chronic myeloid leukemia (CML) of five pregnant women during and after pregnancy. CML was diagnosed during pregnancy in three patients. Pregnancy was confirmed during CML in two patients: in one in the 21st week of pregnancy while on imatinib, in another in the 12th week during the interferon treatment. Interferon with leukapheresis when needed was applied in the 2nd and 3rd trimester. All patients except one achieved complete hematological response during pregnancy. After delivery four patients achieved partial cytogenetic response on imatinib and two patients achieved major molecular response after crossover to dasatinib.

• MeSH
• benzamidy MeSH
• chronická myeloidní leukemie farmakoterapie   terapie   MeSH
• dasatinib MeSH
• dospělí MeSH
• imatinib mesylát MeSH
• interferony terapeutické užití   MeSH
• leukaferéza MeSH
• lidé MeSH
• nádorové komplikace v těhotenství farmakoterapie   terapie   MeSH
• piperaziny terapeutické užití   MeSH
• protinádorové látky terapeutické užití   MeSH
• pyrimidiny terapeutické užití   MeSH
• těhotenství MeSH
• thiazoly terapeutické užití   MeSH
• vedení porodu * MeSH
• Check Tag
• dospělí MeSH
• lidé MeSH
• těhotenství MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• Názvy látek
• benzamidy MeSH
• dasatinib MeSH
• imatinib mesylát MeSH
• interferony MeSH
• piperaziny MeSH
• protinádorové látky MeSH
• pyrimidiny MeSH
• thiazoly MeSH

BACKGROUND: Peripheral blood stem cells are the preferred source for transplantation of hematopoiesis in patients with non-Hodgkin's lymphoma. Application of hematopoietic growth factors is a part of the mobilization chemotherapy regimen. Time overlap of the highest leukocyte and CD34+ cell count is required for optimal graft collection. Authors analyzed the effect of two growth factors (leridistim and filgrastim) on the kinetics and phenotype of CD34+ cells in patients with non-Hodgkin's lymphoma indicated for autologous peripheral blood stem cell transplantation. METHODS AND RESULTS: Authors analyzed phenotype of CD34+ cell subpopulations and their kinetics in peripheral blood and leukapheresis products by flow cytometry during mobilization and graft collection. Statistically significant differences in expression of lineage-committed antigens between growth factors were found (CD3, CD5--T-lineage, CD56 NK-lineage, CD20 for B-lineage, p < 0.05), as well as for lineage non-specific antigens (CD38, p < 0.05 and CD54, p < 0.01). The most significant divergence was observed between CD34+CD19+ subpopulations of leridistim and filgrastim stimulated blood and graft (p < 0.001). CONCLUSIONS: Expression of lineage-committed antigens on CD34+ subpopulations between two growth factors was statistically different. Kinetics of CD34+ cells during mobilization regimen with leridistim was not superior to filgrastim concerning the quality of graft.

• MeSH
• antigeny CD34 analýza   MeSH
• dospělí MeSH
• faktor stimulující kolonie granulocytů farmakologie   MeSH
• filgrastim MeSH
• imunofenotypizace MeSH
• interleukin-3 farmakologie   MeSH
• kmenové buňky imunologie   MeSH
• leukaferéza MeSH
• leukocyty imunologie   MeSH
• lidé středního věku MeSH
• lidé MeSH
• mobilizace hematopoetických kmenových buněk * MeSH
• nehodgkinský lymfom terapie   MeSH
• rekombinantní fúzní proteiny farmakologie   MeSH
• rekombinantní proteiny MeSH
• transplantace periferních kmenových buněk * MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• ženské pohlaví MeSH
• Publikační typ
• anglický abstrakt MeSH
• časopisecké články MeSH
• Názvy látek
• antigeny CD34 MeSH
• faktor stimulující kolonie granulocytů MeSH
• filgrastim MeSH
• interleukin-3 MeSH
• leridistim MeSH Prohlížeč
• rekombinantní fúzní proteiny MeSH
• rekombinantní proteiny MeSH